Algehele overleving in de trials kon niet bevredigend worden verklaard door verschillen in de incidentie van trombose en verwante complicaties tussen hen die recombinant humaan erythropoëtine ontvingen en controles. ###>Overall survival outcome in the trials could not be statisfactorily explained by differences in the incidence of thrombosis and related complications between those given recombinant human erythropoietin and those in the control group.